2月4日，Turnstone生物制药公司因制造成本过高，终止了其最后一个临床阶段的肿瘤浸润淋巴细胞（TIL）疗法项目 TIDAL-01 ，并计划进一步裁员。此举紧随该公司去年十月裁员60%之后，旨在最大限度地提高股东价值。TIDAL-01 是其目前唯一一个临床实验项目，正在多个 I 期临床试验中进行评估，用于治疗包括转移性结直肠癌、头颈癌和葡萄膜黑色素瘤等实体肿瘤。在 STARLING I ...

Emblaveo marks the first and only fixed-dose intravenous monobactam/β-lactamase inhibitor combination antibiotic to be ...

智通财经APP获悉，艾伯维(ABBV.US)公司宣布，美国FDA已批准该公司与辉瑞(PFE.US)联合开发的Emblaveo(aztreonam和avibactam)上市，与甲硝唑联合使用，治疗18岁及以上复杂性腹腔内感染(cIAI)患者，包括由多种 ...

In February 2010, aztreonam for inhalation solution (Cayston; Gilead) — an inhalable formulation of the monobactam antibiotic aztreonam and lysine — was approved by the US FDA to improve ...

AbbVie has announced that the US Food and Drug Administration (FDA) has approved its Pfizer-partnered Emblaveo ...

AbbVie has received US Food and Drug Administration (FDA) approval for Emblaveo (aztreonam and avibactam) to be used in ...

The intravenous antibiotic Emblaveo, a combination of aztreonam and avibactam approved in Europe last year, was developed in ...

Find all the commercial and brand names of generic drug called Aztreonam. This is an invaluable reference resource for healthcare professionals, patients, caregivers and anyone in need of ...

AbbVie announced that the US FDA has approved aztreonam and avibactam (Emblaveo), in combination with metronidazole, for ...

AbbVie receives US FDA approval for Emblaveo to treat adults with complicated intra-abdominal infections with limited or no treatment options: North Chicago, Illinois Monday, Febr ...

Emblaveo is a fixed-dose IV treatment that combines aztreonam, a monobactam antibiotic, and avibactam, a β-lactamase inhibitor.

NORTH CHICAGO, Ill. - The U.S. Food and Drug Administration (FDA) has approved EMBLAVEO™ (aztreonam and avibactam) for the treatment of adults with complicated intra-abdominal infections (cIAI) with ...